Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Long-Term Debt Repayments (2016 - 2020)

Historic Long-Term Debt Repayments for Viridian Therapeutics, Inc.\DE (VRDN) over the last 6 years, with Q4 2020 value amounting to $9.0 million.

  • Viridian Therapeutics, Inc.\DE's Long-Term Debt Repayments rose 79600.0% to $9.0 million in Q4 2020 from the same period last year, while for Sep 2021 it was $9.0 million, marking a year-over-year increase of 28405.49%. This contributed to the annual value of $10.3 million for FY2020, which is 34119.16% up from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Long-Term Debt Repayments of $9.0 million as of Q4 2020, which was up 79600.0% from $333000.0 recorded in Q2 2020.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Long-Term Debt Repayments ranged from a high of $9.0 million in Q4 2020 and a low of $333000.0 during Q4 2016
  • Its 4-year average for Long-Term Debt Repayments is $1.6 million, with a median of $500000.0 in 2017.
  • Its Long-Term Debt Repayments has fluctuated over the past 5 years, first soared by 156500.0% in 2016, then changed by 0.0% in 2020.
  • Viridian Therapeutics, Inc.\DE's Long-Term Debt Repayments (Quarter) stood at $333000.0 in 2016, then soared by 851.05% to $3.2 million in 2017, then tumbled by 68.42% to $1.0 million in 2019, then skyrocketed by 796.0% to $9.0 million in 2020.
  • Its Long-Term Debt Repayments was $9.0 million in Q4 2020, compared to $333000.0 in Q2 2020 and $1.0 million in Q1 2020.